Home › Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for...
 

Keywords :   


Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for...

2014-09-16 12:26:38| Chemicals - Topix.net

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. The study, called ARAMIS, evaluates ODM-201 in men with castration-resistant prostate cancer who have rising Prostate Specific Antigen levels and no detectable metastases.

Tags: iii begin trial phase

Category:Chemicals

Latest from this category

All news
28.09Weekly Recap: AkzoNobel, BASF, Axalta, PPG Top This Weeks Stories
27.09Positive Development for Jotun After First Eight Months of 2028
27.09Graco Signs Definitive Agreement to Acquire Corob
27.09BASF Presents New Corporate Strategy
26.09Advanced Polymer Coatings Signs Deal to Coat for New Build Tankers Union Maritime
26.09Jeff McManus Appointed Senior VP of Americas at allnex
26.09AkzoNobel Develops Particle Technology for Metal Effect Powder Coatings
26.09Behr Paint Company Introduces Women in Paint in Canada
Chemicals »
29.09Tropical Storm Joyce Graphics
29.09Tropical Storm Joyce Forecast Advisory Number 9
29.09Summary for Tropical Storm Joyce (AT1/AL112024)
29.09Hurricane Isaac Graphics
29.09Summary for Hurricane Isaac (AT5/AL102024)
29.09Oasis ticket seller and promoter bosses get 14.8m
29.09Atlantic Tropical Weather Outlook
29.09Eastern North Pacific Tropical Weather Outlook
More »